Protein Carbonylation Contributes to Prothrombotic Fibrin Clot Phenotype in Acute Ischemic Stroke: Clinical Associations.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 31 10 2023
pubmed: 5 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Acute ischemic stroke (AIS) is associated with enhanced oxidative stress and unfavorably altered fibrin clot properties. We investigated determinants of plasma protein carbonylation (PC) in AIS, its impact on the prothrombotic state, and prognostic value during follow-up. We included 98 consecutive AIS patients aged 74±12 years (male:female ratio, 50:48 [51%:49%]) at the Neurology Center in Warsaw, Poland, between January and December 2014. As many as 74 (75.5%) patients underwent thrombolysis, and 24 were unsuitable for thrombolysis. We determined plasma PC, along with thrombin generation, fibrin clot permeability, and clot lysis time on admission, at 24 hours, and 3 months. Stroke severity was assessed using the National Institutes of Health Stroke Scale and stroke outcome with the modified Rankin Scale. Hemorrhagic transformation was assessed on the computed tomography scan within 48 hours from the symptom onset, while stroke-related mortality was evaluated at 3 months. On admission, PC levels (median, 4.61 [3.81-5.70] nM/mg protein) were associated with the time since symptom onset (r=0.41; Elevated plasma PC levels in patients with AIS, related to prothrombotic fibrin clot properties, are associated with stroke severity. Thrombolysis reduces the extent of PC. The current study suggests a prognostic value of PC in AIS.

Sections du résumé

BACKGROUND BACKGROUND
Acute ischemic stroke (AIS) is associated with enhanced oxidative stress and unfavorably altered fibrin clot properties. We investigated determinants of plasma protein carbonylation (PC) in AIS, its impact on the prothrombotic state, and prognostic value during follow-up.
METHODS METHODS
We included 98 consecutive AIS patients aged 74±12 years (male:female ratio, 50:48 [51%:49%]) at the Neurology Center in Warsaw, Poland, between January and December 2014. As many as 74 (75.5%) patients underwent thrombolysis, and 24 were unsuitable for thrombolysis. We determined plasma PC, along with thrombin generation, fibrin clot permeability, and clot lysis time on admission, at 24 hours, and 3 months. Stroke severity was assessed using the National Institutes of Health Stroke Scale and stroke outcome with the modified Rankin Scale. Hemorrhagic transformation was assessed on the computed tomography scan within 48 hours from the symptom onset, while stroke-related mortality was evaluated at 3 months.
RESULTS RESULTS
On admission, PC levels (median, 4.61 [3.81-5.70] nM/mg protein) were associated with the time since symptom onset (r=0.41;
CONCLUSIONS CONCLUSIONS
Elevated plasma PC levels in patients with AIS, related to prothrombotic fibrin clot properties, are associated with stroke severity. Thrombolysis reduces the extent of PC. The current study suggests a prognostic value of PC in AIS.

Identifiants

pubmed: 37795592
doi: 10.1161/STROKEAHA.123.043628
doi:

Substances chimiques

Fibrin 9001-31-4
Thrombin EC 3.4.21.5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2804-2813

Auteurs

Michał Błaż (M)

Department of Neurology, John Paul II Hospital, Krakow, Poland (M.B.)., Jagiellonian University Medical College, Krakow, Poland.

Joanna Natorska (J)

Department of Thromboembolic Diseases, Institute of Cardiology (J.N., M.Z., A.U.), Jagiellonian University Medical College, Krakow, Poland.

Jan P Bembenek (JP)

Department of Clinical Neurophysiology (J.P.B.), Institute of Psychiatry and Neurology, Warsaw, Poland.

Anna Członkowska (A)

2nd Department of Neurology (A.C.), Institute of Psychiatry and Neurology, Warsaw, Poland.

Michał Ząbczyk (M)

Department of Thromboembolic Diseases, Institute of Cardiology (J.N., M.Z., A.U.), Jagiellonian University Medical College, Krakow, Poland.

Maciej Polak (M)

Department of Epidemiology and Population Studies, Institute of Public Health (M.P.), Jagiellonian University Medical College, Krakow, Poland.

Anetta Undas (A)

Department of Thromboembolic Diseases, Institute of Cardiology (J.N., M.Z., A.U.), Jagiellonian University Medical College, Krakow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH